StreetInsider.com News Articles

Rogers Corporation Schedules Third Quarter 2026 Earnings Call for October 27

Tue, 13 Oct 2026 16:05:00 -0400

CHANDLER, Ariz.--(BUSINESS WIRE)-- Rogers Corporation (NYSE: ROG) (“Rogers”) will announce third quarter 2026 results after market close on October 27, 2026. The company will hold a conference call at 5:00 pm ET to discuss the results. The call will be hosted by Ali El-Haj, President and Chief Executive Officer, who will be joined by Laura Russell, Senior Vice President and Chief Financial Officer.

A live webcast of the call and the accompanying presentation will be available on Rogers’ Investor Relations website at https://www.rogerscorp.com/investors. A webcast replay will be available on

Rogers Corporation Schedules Third Quarter 2026 Earnings Call for October 27

Tue, 13 Oct 2026 16:05:00 -0400

A live webcast of the call and the accompanying presentation will be available on Rogers’ Investor Relations website at https://www.rogerscorp.com/investors. A webcast replay will be available on

Rogers Corp (ROG) PT Raised to $225 at B.Riley

Thu, 01 Oct 2026 08:39:04 -0400

B.Riley analyst Craig Ellis raised the price target on Rogers Corp (NYSE: ROG) to $225.00 (from $200.00) while maintaining a Buy rating.

Rogers Corporation Provides 2030 Financial Targets at 2026 Investor Day

Wed, 30 Sep 2026 16:05:00 -0400

Company outlines path to $1.5 billion in revenue, a 26% Adjusted EBITDA margin and $14.00 of Adjusted EPS by 2030

CHANDLER, Ariz.--(BUSINESS WIRE)-- Rogers Corporation (NYSE: ROG) (“Rogers”) today presented its strategy to accelerate growth, expand profitability and increase earnings through 2030 at the Company’s 2026 Investor Day.

The event featured presentations from Ali El-Haj, Rogers’ President and Chief Executive Officer; Laura Russell, Senior Vice President and Chief Financial Officer; and other members of the leadership team.

“We are excited to share our plan to build a higher-growth, higher-performing Rogers,” said Ali El-Haj, President and Chief Executive Officer. “Our

Rogers Corporation Provides 2030 Financial Targets at 2026 Investor Day

Wed, 30 Sep 2026 16:05:00 -0400

Company outlines path to $1.5 billion in revenue, a 26% Adjusted EBITDA margin and $14.00 of Adjusted EPS by 2030

“We are excited to share our plan to build a higher-growth, higher-performing Rogers,” said Ali El-Haj, President and Chief Executive Officer. “Our

Rogers Corporation to Host Investor Day on September 30, 2026

Wed, 30 Sep 2026 06:55:00 -0400

CHANDLER, Ariz.--(BUSINESS WIRE)-- Rogers Corporation (NYSE:ROG) (“Rogers”) will host an Investor Day, Wednesday, September 30, 2026, in New York City.

The event will include presentations from Ali El-Haj, Rogers’ President and Chief Executive Officer; Laura Russell, Senior Vice President and Chief Financial Officer; and other members of the leadership team. An interactive Q&A session will follow the presentations.

The presentations will highlight Rogers’ strategy, growth opportunities and financial objectives through 2030.

The event will begin at 9:00 a.m. ET and is expected to conclude by approximately 11:30 a.m. ET. A live webcast of the event, presentation materials and an on-demand

Rogers Corporation to Host Investor Day on September 30, 2026

Wed, 30 Sep 2026 06:55:00 -0400

CHANDLER, Ariz.--(BUSINESS WIRE)-- Rogers Corporation (NYSE:ROG) (“Rogers”) will host an Investor Day, Wednesday, September 30, 2026, in New York City.

The presentations will highlight Rogers’ strategy, growth opportunities and financial objectives through 2030.

The event will begin at 9:00 a.m. ET and is expected to conclude by approximately 11:30 a.m. ET. A live webcast of the event, presentation materials and an on-demand

Rogers Corporation Announces Investor Day on September 30, 2026

Wed, 09 Sep 2026 16:38:00 -0400

CHANDLER, Ariz.--(BUSINESS WIRE)-- Rogers Corporation (NYSE:ROG) (“Rogers”) today announced that it will host an Investor Day on Wednesday, September 30, 2026, in New York City. Rogers’ President and CEO Ali El-Haj and other members of the senior leadership team will provide details on Rogers’ strategy, key growth opportunities, capital allocation priorities and multi-year financial objectives. The event will include formal presentations from Rogers’ management team, followed by a question-and-answer session.

The event will begin at 9:00 a.m. ET and is expected to conclude by approximately 11:30 a.m. ET. Due to limited capacity, in-person attendance is by invitation only.

Rogers Corporation Announces Investor Day on September 30, 2026

Wed, 09 Sep 2026 16:38:00 -0400

The event will begin at 9:00 a.m. ET and is expected to conclude by approximately 11:30 a.m. ET. Due to limited capacity, in-person attendance is by invitation only.

Form 4 ROGERS CORP For: Sep 05 Filed by: Russell Laura

Wed, 09 Sep 2026 14:25:00 -0400

si-local-file:///var/storage/secattach/20260909/27042098.html

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche (SIX: RO, ROG; OTCQX: RHHBY) has received FDA approval to expand the use of two companion diagnostic tests to identify HER2-positive metastatic gastroesophageal adenocarcinoma (GEA) patients eligible for treatment with Jazz Pharmaceuticals' ZIIHERA (zanidatamab-hrii), according to a company statement.

The approved tests — the PATHWAY HER2 (4B5) Rabbit Monoclonal Primary Antibody test and the VENTANA HER2 Dual ISH DNA Probe Cocktail — are now indicated for use in patients with metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma. The approval covers identification of patients who may be eligible for two ZIIHERA-containing regimens, both of which are FDA approved for first-line treatment

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche wins FDA nod for HER2 companion diagnostics in GEA

Wed, 26 Aug 2026 14:52:56 -0400

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA